Review
Copyright ©The Author(s) 2021.
World J Gastroenterol. Sep 28, 2021; 27(36): 6025-6038
Published online Sep 28, 2021. doi: 10.3748/wjg.v27.i36.6025
Table 1 Prevalence of hepatitis B surface antigen among pre- vs post-hepatitis B vaccine introduction populations in some sub-Saharan African countries
Country
Year of hepatitis B vaccine introduction1
Prevalence of HBsAg (%)
Pre-vaccine introduction
Post-vaccine introduction
< 15-yr-olds
≥ 15-yr-olds
Burundi200411.0[15]2.6[16]1.0-4.6[17]
Democratic Republic of Congo2007> 20.7[18]2.2[19]3.7[19]
Ethiopia200711.0[20]4.4[21]7.4[22]
Gambia199020.0[23]0.4[24]10.0[25]
Kenya200211.4[26]0.9[16]3.4[27]
Mali2003> 8.7[28]4.9[16]8.5[16]
Mozambique200114.6[29]3.7[16]4.5[30]
Namibia200914.0[31]2.7[32]1.8[33]
Nigeria200413.3[34]11.5[35]8.2[36]
Rwanda2002Approximately 5.0[37]1.7[16]2.2[38]
Senegal200411.8[39]1.6[40]> 11.0[41]
South Africa19959.6[15]0.4[42]4.0[43]
Uganda200210.3[44]0.6[45]4.1[45]
Zimbabwe200015.4[46]4.4[16]3.3[47]